阿司匹林或可作为有静脉血栓栓塞史患者行全关节置换术的合适预防措施
本研究为单机构回顾性队列研究,纳入2008年至2020年间36,333例行全关节置换术的患者,其中1,087例(3.0%)有静脉血栓栓塞(VTE)史且未接受长期非阿司匹林抗凝。倾向性评分匹配及多因素回归分析显示,有VTE史患者使用阿司匹林与使用其他预防措施相比,后续VTE发生率无显著差异,阿司匹林未增加VTE风险。作者认为,尽管有VTE史患者基线风险较高,阿司匹林或可作为该人群合适的VTE预防措施。
要点
- 有VTE史患者行全关节置换术后VTE发生率为1.4%,无VTE史者为0.9%(p=0.03)。
- 有VTE史患者中,阿司匹林组VTE发生率为0.4%,其他预防组为1.5%(p=0.208)。
- 倾向性评分匹配后两组VTE率分别为2.2%与0.55%(p=0.372),无显著差异。
核心结论
- 有VTE史患者行全关节置换术后基线VTE风险增高,但阿司匹林或可作为该人群合适的VTE预防措施。
研究设计与样本
- 单机构回顾性队列研究,纳入2008年至2020年间36,333例行全关节置换术的患者,采用倾向性评分匹配及多因素回归分析控制混杂因素。
主要发现
- 36,333例患者中1,087例(3.0%)有VTE史且未接受长期非阿司匹林抗凝。
- 有VTE史患者后续VTE发生率为1.4%,无VTE史患者为0.9%(p=0.03)。
- 有VTE史患者中,接受阿司匹林者VTE发生率为0.4%,接受其他VTE预防者为1.5%(p=0.208)。
- 倾向性评分匹配后两组VTE发生率分别为2.2%与0.55%(p=0.372)。
- 回归分析中,阿司匹林给药与后续VTE风险增加无关(调整比值比0.32 [95%置信区间0.02至1.66];p=0.274)。
临床怎么用
- 作者认为,尽管有VTE史患者基线VTE风险增高,阿司匹林或可作为该人群合适的VTE预防措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, aspirin has become a popular agent for venous thromboembolism (VTE) prophylaxis following total joint arthroplasty (TJA). Yet patients with a history of VTE are often given more aggressive prophylactic agents because of their increased baseline risk. The purpose of this study was to assess whether aspirin is an effective prophylactic agent in patients with a history of VTE. METHODS: This was a single-institution, retrospective cohort study. The electronic clinical records of 36,333 patients undergoing TJA between 2008 and 2020 were reviewed. Data on demographic characteristics, comorbidities, intraoperative factors, and postoperative complications were collected. A propensity score-matched analysis was performed, as well as a multivariate regression analysis to account for confounders. RESULTS: Of the 36,333 patients undergoing TJA, 1,087 patients (3.0%) had a history of VTE and were not receiving chronic non-aspirin. The risk for subsequent VTE was significantly higher (p = 0.03) in patients with a history of VTE (1.4%) compared with patients without prior VTE (0.9%). However, the incidence of VTE was not significantly lower (p = 0.208) in patients with a history of VTE who received aspirin (0.4%) compared with patients who received other VTE prophylaxis (1.5%). Propensity score matching showed no difference in VTE rates between the 2 groups (2.2% compared with 0.55%; p = 0.372). In a regression analysis accounting for VTE risk, the administration of aspirin was not associated with an increased risk for subsequent VTE (adjusted odds ratio, 0.32 [95% confidence interval, 0.02 to 1.66]; p = 0.274). CONCLUSIONS: Our findings suggest that, although patients with a history of VTE have an increased baseline risk for subsequent VTE, aspirin may be a suitable VTE prophylaxis in this group of patients. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Ludwick L, Shohat N, Van Nest D, et al. Aspirin May Be a Suitable Prophylaxis for Patients with a History of Venous Thromboembolism Undergoing Total Joint Arthroplasty. J Bone Joint Surg Am. 2022. PMID: 35700090. doi:10.2106/JBJS.21.00601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。